Reviews/Parkinsons Disease Management/Continuous infusion therapy reduces motor fluctuations in advanced Parkinson's
PD DEVICE · PD-04 · v2
The claim says that two infusion therapies — subcutaneous apomorphine and intestinal levodopa gel (LCIG) — cut the daily 'off' periods of advanced Parkinson's disease better than best oral pills. For LCIG the corpus has one short head-to-head trial against oral levodopa [1] showing a clear reduction in off-time, backed by several large real-world cohorts [2][3][4][6][7] and a cross-sectional study [5] that all point the same way. For apomorphine, however, the corpus contains no efficacy study at all; it appears only in a survey of what treatment patients would choose [8]. The one controlled trial was small, lasted 12 weeks, and was company-funded, and the remaining studies had no comparison group. The panel treated the claim as an 'either/or' statement, judged the LCIG evidence strong and consistent enough to carry it, but held back from the top tier because the direct comparison is thin and the apomorphine half is unsupported here.
Only [1] directly compares an infusion against optimised oral levodopa: a 12-week double-blind RCT (35 vs 31 patients) in which LCIG reduced off-time by a between-group difference of -1.91 h (95% CI -3.05 to -0.76; p=0.0015) and increased on-time without troublesome dyskinesia by 1.86 h (p=0.0059). Uncontrolled real-world cohorts corroborate the direction and magnitude: off-time fell by -3.3 h at 36 months [2], by -4.7 h at 12 months [3], and from 6.3 to 1.9 h [6], with dyskinesia duration reduced -29.4% [7] and UPDRS-IV item 39 down 50-55% out to 8 years [4]. A cross-sectional study of 387 patients reports off-time and dyskinesia reductions across treatment-duration strata [5]. No paper in the corpus reports apomorphine efficacy; [8] records it only as a patient preference option. The contested point: The division is between the breadth of supporting data and its design: the direction is unanimous across seven datasets, but only [1] has an oral comparator, and it is a single small 12-week trial. Whether that one controlled result plus uncontrolled, largely sponsor-run cohorts is enough to count the comparative claim as firmly established is the point the panel weighed.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Parkinsons Disease Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Only [1] has an oral comparator; the 'compared with optimised oral therapy' clause rests on a single N=66, 12-week trial. Papers [2]-[7] are uncontrolled before/after designs that cannot separate the infusion effect from regression to the mean, placebo, or intensified management.
The claim names continuous subcutaneous apomorphine as one of two modalities, but the corpus contains no apomorphine efficacy study; [8] mentions it only as a patient-preference option. That half of the disjunctive claim is entirely unevidenced here.
Where it remains uncertain. The comparative claim rests on one N=66, 12-week AbbVie-funded trial [1]; papers [2]-[7] are uncontrolled before/after designs, and no paper [1]-[8] supplies apomorphine efficacy data.
Aleatory
The only comparative estimate comes from 66 analysed patients over 12 weeks [1], so random variation around the -1.91 h difference is non-trivial.
Epistemic
The corpus contains no study measuring apomorphine's effect on motor fluctuations; [8] records it only as a preference. That half of the claim cannot be assessed here.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Only controlled comparison vs optimised oral therapy; establishes significant off-time reduction attributable to infusion
“Mean on-time without troublesome dyskinesia increased by 4.11 h (SE 0.75) in the intestinal gel group and 2.24 h (0.76) in the immediate-release oral group (difference 1.86 [95% CI 0.56 to 3.17]; p=0.0059)”
Panel auditInternal validity: high · scope of inference: Adults aged ≥30 with advanced Parkinson's disease and motor complications over 12 weeks; speaks only to LCIG, not to apomorphine.Key limitations: 12-week duration only · full-analysis set with last-observation-carried-forward imputation · AbbVie-funded · no apomorphine arm
Demonstrates durability of fluctuation reduction to 3 years
“Significant improvements in "Off" time were maintained over 3 years (mean [SD]: -3.3 hours [3.7]; p < 0.001)”
Panel auditInternal validity: low · scope of inference: Advanced PD patients initiating LCIG in routine care over 36 months; speaks only to LCIG, not to apomorphine, and not to a maintained optimised-oral comparator.Key limitations: no concurrent comparator arm · observational routine-care sample · high discontinuation (54.4%) · patient-reported endpoint
Large independent real-world cohort corroborating off-time reduction
“There were reductions of mean daily "Off" time from baseline (BL) (7.1 ± 3.5 h) and "On" time with dyskinesias (5.2 ± 4.5 h) at month 12 (M12) of -4.7 ± 3.4 and -1.7 ± 5.0 h respectively (p < 0.0001; p = 0.0228)”
Panel auditInternal validity: low · scope of inference: Advanced PD patients on LCIG in routine care at 12 months; speaks only to LCIG, not to apomorphine.Key limitations: no concurrent comparator · interim subset analysis · open-label routine care · self-reported diary endpoints
UPDRS-IV item 39 and dyskinesia duration, disability and pain all fell significantly from baseline after LCIG.
Panel auditInternal validity: low · scope of inference: Italian routine-care cohort on LCIG up to 8 years; speaks only to LCIG, not to apomorphine.Key limitations: no concurrent comparator · single-country routine-care cohort · observational design · variable follow-up timing
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The direction is robust and directly tested for LCIG, but reliance on one small controlled trial plus uncontrolled sponsor-run data and the unevidenced apomorphine limb preclude an Established verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No controlled apomorphine evidence. The claim names subcutaneous apomorphine, but no corpus paper reports its efficacy on motor fluctuations; [8] mentions it only as a preference. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial of continuous subcutaneous apomorphine versus optimised oral therapy with off-time as the primary endpoint.
Open question: Does continuous subcutaneous apomorphine reduce motor fluctuations compared with optimised oral therapy in advanced Parkinson's disease? Why it is still open: No corpus paper reports apomorphine efficacy; [8] records it only as a patient preference option.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19